Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03 2024 - 4:30PM
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development, and commercialization of targeted therapies
for breast cancer and beyond, today announced that the Company
granted stock options to two new employees to purchase an aggregate
of 60,000 shares of the Company's common stock, effective as of
December 2, 2024. These awards were approved by the Compensation
Committee of Olema’s Board of Directors and granted under the
Company's 2022 Inducement Plan as an inducement material to the new
employees entering into employment with Olema, in accordance with
Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting
on the first anniversary of the vesting commencement date for such
employee and the remainder vesting in 36 equal monthly installments
over the following three years, subject to the employee being
continuously employed by Olema as of such vesting dates. The stock
options have a 10-year term and an exercise price of $10.21 per
share, equal to the last reported sale price of the Company's
common stock as reported by Nasdaq on December 2, 2024. The stock
options are subject to the terms of the Olema Pharmaceuticals,
Inc., 2022 Inducement Plan.
Olema is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Olema OncologyOlema Oncology is a
clinical-stage biopharmaceutical company committed to transforming
the standard of care and improving outcomes for women living with
cancer. Olema is advancing a pipeline of novel therapies by
leveraging our deep understanding of endocrine-driven cancers,
nuclear receptors, and mechanisms of acquired resistance. Our lead
product candidate, palazestrant (OP-1250), is a proprietary, orally
available complete estrogen receptor (ER) antagonist (CERAN) and a
selective ER degrader (SERD), currently in a Phase 3 clinical trial
called OPERA-01. In addition, Olema is developing a potent KAT6
inhibitor (OP-3136). Olema is headquartered in San Francisco and
has operations in Cambridge, Massachusetts. For more information,
please visit us at www.olema.com.
Media and Investor Relations Contact
Courtney O’KonekVice President, Corporate CommunicationsOlema
Oncologymedia@olema.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Nov 2024 to Dec 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Dec 2023 to Dec 2024